================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
February 19, 2004
TRANSGENOMIC, INC.
(Exact name of registrant as specified in its charter)
Delaware 000-30975
(State of Formation) (Commission File Number)
911789357
(IRS Employer Identification Number)
12325 Emmet Street
Omaha, NE 68164
(Address of principal executive offices) (Zip Code)
(402) 452-5400
(Registrants' telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report)
================================================================================
Item 5. Other Events and Regulation FD Disclosure.
On February 19, 2004, the Company entered into a three-year, $2.75 million
convertible note with Laurus Master Fund, Ltd., and on February 20, 2004, the
Company appointed Gregory T. Sloma to its Board of Directors. A copy of a press
release issued by the Company announcing these events is filed herewith as
Exhibit 99.1 and is incorporated herein by reference.
Item 7. Financial Statements and Exhibits.
(c) Exhibits
99.1 Press Release, dated February 24, 2004, announcing fourth
quarter and fiscal year results of operations and summary
financial position for the registrant's quarter ended December
31, 2003, the signing of a three-year, $2.75 million
convertible note with Laurus Master Fund, Ltd., and the
appointment of Gregory T. Sloma to the Board of Directors.
Item 12. Results of Operations and Financial Condition.
On February 24, 2004, Transgenomic, Inc. (the "Company") issued a press
release announcing results of operations and summary financial position for the
quarter and fiscal year ended December 31, 2003. The Company is attaching the
press release as Exhibit 99.1 to this Current Report on Form 8-K.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
TRANSGENOMIC, INC.
By /s/ Michael J. Draper
------------------------------------------
Michael J. Draper, Chief Financial Officer
February 24, 2004
3